Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Tripolt, NJ; Leber, B; Triebl, A; Köfeler, H; Stadlbauer, V; Sourij, H.
Effect of Lactobacillus casei Shirota supplementation on trimethylamine-N-oxide levels in patients with metabolic syndrome: An open-label, randomized study.
Atherosclerosis. 2015; 242(1):141-144
Doi: 10.1016/j.atherosclerosis.2015.05.005
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Stadlbauer-Köllner Vanessa
- Tripolt Norbert
- Co-Autor*innen der Med Uni Graz
- Köfeler Harald
- Leber Bettina
- Sourij Harald
- Triebl Alexander
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Recent studies in animal models have shown a link between ingestion of dietary phosphatidylcholine (PC), choline, l-carnitine and cardiovascular risk. Intestinal microbiota-dependent metabolism of PC and l-carnitine is involved in formation of trimethylamine (TMA), which is further metabolized to the proatherogenic compound trimethylamine-N-oxide (TMAO). It has been suggested that changes in gut microbiota by supplementation of probiotic drinks might alter TMAO levels. Hence, the aim of this analysis was to investigate the impact of Lactobacillus casei Shirota (LcS) on formation of TMAO in subjects with metabolic syndrome. In a single-center, prospective, randomized-controlled study 30 subjects with metabolic syndrome were randomized to receive either 3 times daily 6.5 × 10(9) CFU (colony-forming units) LcS (probiotic group) or not (standard therapy group) for 12 weeks. TMAO plasma levels were quantified by means of liquid chromatography and tandem mass spectrometry. Thirteen patients in the probiotic group and 15 in the standard therapy group finished the study. Mean age was 52 ± 11 and 55 ± 9 years, respectively. TMAO levels decreased during the intervention period in both groups (from 4.66 ± 2.66 μM to 4.31 ± 2.04 μM in the probiotic group and from 4.64 ± 2.75 μM to 4.40 ± 2.14 μM in the control group). Changes in TMAO between subjects receiving LcS (-0.25 ± 2.39 μM) and controls (-0.34 ± 2.23 μM) were not significantly different (p = 0.510). In conclusion, intake of LcS for 12 weeks did not affect levels of TMAO in patients with metabolic syndrome. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Austria -
- Biomarkers - blood
- Chromatography, Liquid -
- Female -
- Gastrointestinal Microbiome -
- Humans -
- Intestines - microbiology
- Lactobacillus casei - growth & development
- Lactobacillus casei - metabolism
- Male -
- Metabolic Syndrome - blood
- Metabolic Syndrome - diagnosis
- Metabolic Syndrome - microbiology
- Metabolic Syndrome - therapy
- Methylamines - blood
- Middle Aged -
- Probiotics - therapeutic use
- Prospective Studies -
- Tandem Mass Spectrometry -
- Time Factors -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Trimethylamine-N-oxide (TMAO)
- Lactobacillus casei Shirota (LcS)
- Gut microbiota
- Metabolic syndrome
- Microbiome